Clinical trial
A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT03096080 is registered in ClinicalTrials.gov with Kadmon Corporation, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Lead sponsor
- Kadmon Corporation, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 24, 2017
- Completion date
- September 30, 2019
- Enrollment
- 10 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.